Dataset Information

Multi-Omic Evidence of Brain Region Specific APOE Genotype Perturbations in Alzheimer's Disease

ABSTRACT: Simultaneous extraction of proteins and lipids from human frontal cortex and cerebellum brain tissue was performed using the MPLEx procedure for both control and Alzheimer's disease patients. The isolated proteins were then reduced, alkylated, tryptically digested and evaluated with LC-IMS-MS. The proteomics data was matched to an AMT tag database created from pooled and fractionated samples for peptide identification. The extracted lipids were assessed with both LC-MS/MS and LC-IMS-MS to study isomer differences. The lipids were identified using LIQUID software.

INSTRUMENT(S): In-house built IMS-MS with Agilent TOF MS, Orbitrap Fusion Lumos

ORGANISM(S): Homo Sapiens (ncbitaxon:9606)

SUBMITTER: Erin S. Baker

PROVIDER: MSV000092627 | MassIVE | Tue Aug 08 17:08:00 BST 2023

REPOSITORIES: MassIVE

ACCESS DATA

Dataset's files

Source:

			Action	DRS
		Other

Items per page:

1 - 1 of 1

Publications

Deciphering ApoE Genotype-Driven Proteomic and Lipidomic Alterations in Alzheimer's Disease Across Distinct Brain Regions.

Odenkirk Melanie T MT Zheng Xueyun X Kyle Jennifer E JE Stratton Kelly G KG Nicora Carrie D CD Bloodsworth Kent J KJ Mclean Catriona A CA Masters Colin L CL Monroe Matthew E ME Doecke James D JD Smith Richard D RD Burnum-Johnson Kristin E KE Roberts Blaine R BR Baker Erin S ES

Journal of proteome research 20240118 8

Alzheimer's disease (AD) is a neurodegenerative disease with a complex etiology influenced by confounding factors such as genetic polymorphisms, age, sex, and race. Traditionally, AD research has not prioritized these influences, resulting in dramatically skewed cohorts such as three times the number of Apolipoprotein E (APOE) ε4-allele carriers in AD relative to healthy cohorts. Thus, the resulting molecular changes in AD have previously been complicated by the influence of apolipoprotein E dis ...[more]

PMID: 38236019

Similar Datasets

Project description:Sudden cardiac death (SCD) associated with heart failure (HF) is a multifactorial problem requiring a systems level approach applied to suitable experimental animal models with features of the human disease. Here we examine key regulatory pathways underlying the transition from compensated hypertrophy (HYP) to decompensated HF and SCD by integrated analysis of the transcriptome, proteome and metabolome. In a guinea pig model of acquired long QT syndrome and HF/SCD, relative protein abundances from sham-operated, HYP and HF hearts were assessed using isobaric tags for relative and absolute quantification (iTRAQ), prior to liquid chromatography and tandem mass spectrometry (LC-MS/MS). Metabolites were quantified by LC-MS/MS or gas chromatography coupled to MS (GC-MS). Transcriptome profiles were obtained using DNA microarrays. The guinea pig HF proteome exhibited classic biosignatures of cardiac HYP, left ventricular dysfunction, fibrosis, cellular degeneration, inflammation and extravasation. Fatty acid metabolism, mitochondrial transcription/translation factors, antioxidant enzymes, and other mitochondrial processes, were downregulated in HF, but not HYP. Proteins upregulated in HF are consistent with extracellular matrix remodeling, cytoskeletal remodeling, and acute phase inflammation markers. Among metabolites, downregulation of acyl-carnitines was observed in HYP, while fatty acids accumulated in HF. Levels of the tricarboxylic acid (TCA) cycle metabolite, citrate, and the potent inhibitor, 2-methylcitrate, increased upon transition from HYP to HF. Correlation of the magnitude of transcript and protein changes in HF is weak (R2=0.23), indicating that targeting transcript/proteome may reveal inform post-transcriptional gene regulation in HF. Proteome/Metabolome integration suggests metabolic bottlenecks in fatty acyl-CoA processing by carnitine palmitoyl transferase (CPT1B) as well as TCA cycle inhibition. We present a model in which hallmarks of acute signaling in HF, including Ca2+ dysregulation and low cAMP levels, are coupled to mitochondrial metabolic and antioxidant defects, through a CREB/PGC1-alpha transcriptional axis.